SANUWAVE HEALTH REPORTS FIRST QUARTER 2020

SANUWAVE HEALTH REPORTS FIRST QUARTER

2020 FINANCIAL RESULTS

SUWANEE, GA, May 18, 2020 - SANUWAVE Health,

Inc. (OTCQB:SNWV) reported financial results for the quarter

ended March 31, 2020 with the SEC on Friday, May 15, 2020. The

Company will also host a conference call today, May 18, 2020, at

10:00 a.m. Eastern Time.

Highlights from the quarter:

System solutions to treat patients in

a home setting. Initial 10 sites successfully targeted for

have begun in Open States in earnest as of last week.

Backlog for placements continues to grow for when open activity

resumes, everywhere.

Entered into an agreement to place

Systems with Mobile Health Systems

(MHS), a business recently launched by former SANUWAVE President

roughly $200,000 in monthly expense savings during

expected to be received by the end of May/early June.

into an exclusive worldwide license agreement for

NanoVibronix's surface acoustic wave ultrasound technology,

in the wound care market.

filed a patent for use of shockwaves to treat respiratory ailments

including viral infections such as COVID-19, Chronic Obstructive

Pulmonary Disease (COPD), Cystic Fibrosis, Idiopathic Pulmonary

Fibrosis (IPF), Pneumonia, and Bronchitis.

a grant proposal to the NIH (National Institute of Health) for

Phase 1 funding to explore shockwave pre-clinical research in the

area of respiratory ailments, specifically on the treatment of

COVID-19 and its debilitating health effects.

a grant proposal pitch to the NSF (National Science Foundation) for

the use of shockwaves in the COVID-19 treatment. SANUWAVE was

incited to submit a full-proposal on the subject for Phase 1

funding, which will be done at the beginning of June.

host conference call Thursday May 28 to review new strategic

The pandemic is impacting all medical businesses, including

SANUWAVE. We are adapting quickly as a company by listening to and

meeting our customer's needs. The global wound market does

not stop just because a pandemic is in place, but how and where

those patients can be treated needs to adjust. The bulk of diabetic

foot ulcer (DFU) patients will still be treated and are currently

being treated in the wound care centers, but many patients will

need to be treated with a new paradigm, which

can address. The first quarter was

disappointing from a revenue perspective, regardless of the

pandemic, so the leadership team has taken some restructuring

efforts to improve how we do business. These changes were

implemented during April and May and should show great signs of

improvement during the remainder of the second quarter and through

out 2020. These changes coupled with certain markets opening up

give us more hope of returning to a better normality for placements

and a focus on revenue per site. We also implemented cost savings

to provide a longer runway to reach profitability later this

year. stated Kevin Richardson, CEO.

COVID-19 Business Update

Our top priority is the safety and well being of our employees,

along with the clinicians and medical communities they serve. We

have opened our office in Suwanee, GA with social distancing and

safety measures in place and continue to monitor the guidelines. We

have also continued a work from home schedule for employees, as

needed, unless asked to participate at a client site for training,

install or treatment assistance. Many hospitals are not allowing

sales representatives to enter the premises and many patients are

being asked to stay home. This is having an impact on our

procedures and placements in 2020 and is expected to continue until

restrictions at the hospital level begin to open up again. SANUWAVE

has begun to see placements pick up in the past week for the first

time in several weeks, as new installations occurred in the

Southeast Region where the states have eased restrictions.

International orders have also been picking up in the past weeks as

restrictions are lifted. The diabetic foot ulcer (DFU) patient

doesn't not go away, their ailment, actually gets worse when

not treated. Our team is also continuing to build the back log of

In our dosage clinical study from Poland, after an interruption of

few weeks, the patients started to come back for the

System treatments in increased numbers

when compared to pre COVID-19 crisis, which is an indication of the

great results that we see in this study and the level of trust that

our patients have in the dermaPACE

In light of the inability for certain patients to receive care in a

hospital or outpatient-based setting, SANUWAVE Health was quick to

deploy our Home Health dermaPACE

Mobile System treatments. We are

launching with 10 current customers and will begin treating

patients during May. The dermaPACE

Mobile System is a unique advanced

care modality that can be transported and brought into the home

setting, unlike a hyperbaric machine or other surgical procedures.

Our customers are looking for ways to treat their patients and also

generate revenue to support their staffing levels. SANUWAVE's

mobile model meets the needs of our customers. This new revenue

channel will incorporate telemedicine to help during the covid-19

pandemic, but also for the future of the wound

SANUWAVE is encouraged that demand is beginning to show signs of

life, but implemented a series of cost savings initiatives, which

were implemented in early May. The cost savings covered a voluntary

expense reduction, specifically targeting senior management,

eliminating travel and entertainment (T&E), and tradeshows,

cutting outside consultants and advisors, and streamlining many

internal processes. These savings have reduced our monthly burn by

roughly $200,000. At the same time the sales and account management